PFIZER INC
PFE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PFE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PFE
Pfizer Inc. is a global biopharmaceutical company focused on R&D, manufacturing, and commercialization of medicines and vaccines, with a sharpened pipeline and ongoing cost realignment program.
Key risk: R&D failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$159.36B
Cash Runway
9.7 moLead Asset
abrilada (Approved)Next Catalyst
Phase3_Topline · Sep 19, 2026Financial data as of Jun 28, 2026.
Tracking 29 pipeline candidates · 210 clinical trials · 45 catalysts · 23 FDA decisions for PFIZER INC.
Pfizer Inc. is a global biopharmaceutical company focused on R&D, manufacturing, and commercialization of medicines and vaccines, with a sharpened pipeline and ongoing cost realignment program.
- Pfizer reported total revenue of $15,034.0M and net income of -$248.0M as of 2026-06-28 [sec].
- Cash and equivalents stood at $1,034.0M, with shareholders' equity of $86,476.0M and total debt of $63,100.0M as of 2026-06-28 [sec].
- As of February 3, 2026, Pfizer had ~200 projects in its product pipeline [sec · filed 2026-03-12].
- Pfizer achieved an end-to-end success rate of 8 percent from first in human to approval by the end of 2025 [sec · filed 2026-03-12].
- The company delivered $4.0 billion in net cost savings from its ongoing cost realignment program, with an increased target of ~$4.5 billion by end of 2025 [sec · filed 2025-03-13].
What works
- Pfizer strengthened its leadership in Oncology through the Seagen integration, becoming the third largest biopharmaceutical company in Oncology in the U.S. by revenue as of December 31, 2024 [sec · filed 2025-03-13].
- The company has a robust pipeline with 14 regulatory approvals, 6 regulatory submissions, and 7 pivotal study starts in a strong year [sec · filed 2025-03-13].
- Pfizer reached a voluntary agreement with the U.S. Government to lower drug costs, providing pricing clarity and a three-year grace period from certain tariffs [sec · filed 2026-03-12].
- Key products such as Vyndaqel family, Eliquis, Xtandi, and Nurtec ODT/Vydura delivered strong commercial performance [sec · filed 2025-03-13].
What to weigh
- Pfizer reported a net loss of -$248.0M as of 2026-06-28, indicating ongoing profitability challenges [sec].
- The company carries significant total debt of $63,100.0M as of 2026-06-28, which may impact financial flexibility [sec].
- Revenues for 2023 declined 41% operationally year-over-year, primarily due to a significant drop in COVID-19 product sales [sec · filed 2024-03-14].
- The R&D success rate of 8% from first in human to approval highlights the inherent risk and low probability of success in drug development [sec · filed 2026-03-12].
From the filings
Quoted directly from source documents.
Pfizer's R&D pipeline includes approximately 200 projects as of early 2026.
“~200 | | | >448M | | | | | | | | | | | | | | | | | | | | | | projects in our product pipeline as ofFebruary 3, 2026”
SEC filings · March 12, 2026
Pfizer achieved an 8% end-to-end success rate from first in human to approval by end of 2025.
“By the end of 2025, Pfizer achieved an end-to-end success rate of 8 percent -- from first in human (FIH) to appr”
SEC filings · March 12, 2026
Pfizer is the third largest biopharmaceutical company in Oncology in the U.S. by revenue as of December 31, 2024.
“Third largest biopharmaceutical company in Oncology in the U.S. by revenue as of December 31, 2024”
SEC filings · March 13, 2025
Pfizer delivered $4.0 billion in net cost savings from its cost realignment program.
“Delivered on our $4.0 billion net cost savings target from ongoing cost realignment program and increased overall savings target to ~$4.5 billion by end of 2025”
SEC filings · March 13, 2025
Catalyst timeline
- 2026-09-19 · Phase3_Topline · enzalutamide — Phase 3 topline results for enzalutamide plus leuprolide or monotherapy in prostate cancer.
- 2026-12-30 · Phase3_Topline · vepdegestrant — Phase 3 topline data for vepdegestrant (ARV-471) plus palbociclib in breast cancer.
- 2026-12-31 · Phase3_Topline · brentuximab — Phase 3 topline results for brentuximab in a randomized, double-blind study.
- 2027-06-30 · Phase3_Topline · talazoparib — Phase 3 topline data for talazoparib with enzalutamide in metastatic prostate cancer.
Risks & what to watch (4)›
Key risks
- R&D failure risk — Low 8% success rate from first-in-human to approval highlights high attrition in drug development [sec · filed 2026-03-12].
- High debt burden — Total debt of $63.1B as of 2026-06-28 may constrain financial flexibility and increase interest costs [sec].
- Revenue decline from COVID products — 2023 revenues fell 41% operationally year-over-year due to declining COVID-19 product sales [sec · filed 2024-03-14].
- Regulatory and pricing uncertainties — Voluntary U.S. government agreement on drug pricing may impact future revenue and margins [sec · filed 2026-03-12].
What to watch
- Upcoming Phase 3 topline results for enzalutamide (2026-09-19) and vepdegestrant (2026-12-30) [catalyst_timeline].
- Phase 3 topline data for brentuximab (2026-12-31) and talazoparib (2027-06-30) [catalyst_timeline].
- Progress on cost realignment program targeting ~$4.5 billion in net savings by end of 2025 [sec · filed 2025-03-13].
- Commercial performance of key products like Eliquis, Xtandi, and Vyndaqel family [sec · filed 2025-03-13].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run PFIZER INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PFIZER INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
9.7 months
D/E 1.36 · 0% dilution
Lead: Approved
29 candidates
45 upcoming, next in ~20d
3 buys · 2 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2,932
Total value held
$114.06B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 738,860,024 | $20.75B |
| blackrock, inc. | 498,257,550 | $13.99B |
| state street corp | 301,589,865 | $8.47B |
| geode capital management, llc | 133,561,742 | $3.74B |
| vanguard portfolio management llc | 116,734,695 | $3.28B |
| morgan stanley | 92,685,370 | $2.60B |
| northern trust corp | 62,026,552 | $1.74B |
| massachusetts financial services co /ma/ | 56,911,830 | $1.62B |
| state farm mutual automobile insurance co | 54,508,560 | $1.53B |
| bank of new york mellon corp | 53,879,900 | $1.51B |
Showing top 10 of 2,932 institutional holders of PFIZER INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.4%
- Days to cover
- 3.5
- Shares short
- 133,414,052
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PFE short interestGovernance
Frequently asked questions
What is the AI investment thesis for PFIZER INC?
Pfizer Inc. is a global biopharmaceutical company focused on R&D, manufacturing, and commercialization of medicines and vaccines, with a sharpened pipeline and ongoing cost realignment program.
What is PFIZER INC's lead drug candidate?
PFIZER INC's most advanced tracked candidate is abrilada (Approved).
What is PFIZER INC's next catalyst?
PFIZER INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot" — expected September 19, 2026.
Who is the CEO of PFIZER INC?
Dr. Albert Bourla D.V.M., Ph.D. is the chief executive officer of PFIZER INC (PFE).
Where is PFIZER INC headquartered?
PFIZER INC (PFE) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.